Tag: Ascletis
Ascletis Presented Positive Phase I Clinical Data for Broad-Spectrum Antiviral D…...
--At the dosage of 800 mg ASC10, twice daily (BID), the exposure of the active drug, ASC10-A, is comparable to that of monupiravir's...
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restorati…...
HANGZHOU, China and SHAOXING, China, May 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the Investigational New Drug (IND)...
Ascletis Announces the Latest Results of the Preclinical Studies of Two...
HANGZHOU, China and SHAOXING, China, March 27, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) today announces that the latest preclinical research results of the...
Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacit… –...
HANGZHOU, China and SHAOXING, China, March 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, HKEX: 1672) today announces that it has further expanded its ritonavir...